Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03315286 · ClinicalTrials.gov registry record · NA
Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure
A NA study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- NA
- Development phase
- 111
- Enrollment target
NCT03315286: Completed NA study, sponsored by Weill Medical College of Cornell University.
NCT03315286 is a NA study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 111 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03315286, a NA study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- NA
- Development phase
- 111 participants
- Enrollment target
Study Summary
This study will evaluate the safety and effectiveness of Shade for the management of UV-induced skin complications and data collected from this study will be used to support the proposed indications for use.
Primary Outcome
Clinical counting of new actinic keratosis at 3 month intervals for a total duration of 6 months. Patient's actinic keratosis were counted at baseline (0 months), 3 months and 6 months. The average number of actinic keratosis at 6 months is only reported.
Interventions
- BEHAVIORAL Standard of care counseling
- DEVICE SHADE Ultraviolet Sensor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2017-10-11 |
| Est. Completion | 2019-03-31 |
| Phase | NA |
What the finished NCT03315286 record still lists
NCT03315286 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard of care counseling is the first listed.
NCT03315286 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03315286 about?
NCT03315286 is a clinical study titled "Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure". This study will evaluate the safety and effectiveness of Shade for the management of UV-induced skin complications and data collected from this study will be used to support the proposed indications for use.
What is the current status of trial NCT03315286?
This trial is currently completed. It is a NA study. The enrollment target is 111 participants. The study started on 2017-10-11. Estimated completion is 2019-03-31.
What interventions are being tested in trial NCT03315286?
The interventions under investigation include: Standard of care counseling (BEHAVIORAL), SHADE Ultraviolet Sensor (DEVICE).
Who is sponsoring clinical trial NCT03315286?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03315286's enrollment target sits among peer trials
111 816th of 2000 higher than 1,185 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI